Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.
about
Interleukin-11 for induction of remission in Crohn's diseaseTrichuris suis therapy in Crohn's diseaseThe structure of human interleukin-11 reveals receptor-binding site features and structural differences from interleukin-6Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cellsHow accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)?The impact of JNK inhibitor D-JNKI-1 in a murine model of chronic colitis induced by dextran sulfate sodium.Review article: medical treatment of moderate to severe Crohn's disease.Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition.Evaluation of new therapies for inflammatory bowel disease.IL-11 Attenuates Liver Ischemia/Reperfusion Injury (IRI) through STAT3 Signaling Pathway in Mice.STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease?Novel biological strategies in inflammatory bowel diseases.Biologics in inflammatory bowel disease: how much progress have we made?Biological response modifiers for the treatment of Crohn's disease.Management of ulcerative colitis and Crohn's disease.Safety of biologic therapy.Biologics in Crohn's disease: searching indicators for outcome.Recent advances in the medical therapy of Crohn's disease in childhood.Biologic targeting in the treatment of inflammatory bowel diseases.Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.Investigational agents for Crohn's disease.Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.Cytokine blockade in inflammatory bowel diseases.Translational research and efficacy of biologics in Crohn's disease: a cautionary tale.IL-11 signaling as a therapeutic target for cancer.Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.Non-core region modulates interleukin-11 signaling activity: generation of agonist and antagonist variants.Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.Decreased MAPK- and PGE2-dependent IL-11 production in Gialpha2-/- colonic myofibroblasts.The cardioprotective effect of interleukin-11 against ischemia-reperfusion injury in a heart donor model.New insights into the biological therapy of Crohn’s disease
P2860
Q24200762-EBA38996-52FB-4E42-BC5F-13FE50F61C98Q24685735-DD23F776-4B87-4F0C-AED1-CCC56510137AQ27695574-59B7127F-028C-49D9-9870-5CFFF539E18FQ28236807-0ED6629B-BE6C-4FA3-8736-81B2A2C2192AQ28251305-529626C2-A375-4662-A2E3-58851A3198E9Q30454726-1A0A9B7D-BB6F-40ED-A965-5D6598BD850AQ35145017-F5EA6C6D-2AC1-4533-A863-023BE921D424Q35161097-A903A165-46DC-4066-AF8A-6D1E3FE96CE1Q35216827-D70119B7-063A-4B02-BE53-013424739D6EQ35577573-B6893356-B1E5-4733-A848-905609F880F7Q35589806-2DCB8940-5888-41CF-B2C5-EB9110706A5CQ35787653-2FBDF457-1AA4-4AEA-818F-300F5C045096Q35861158-AFD2EFFC-3B0D-477C-B3C9-D3B25D489DB7Q35925597-B7C30791-1046-49F1-A520-38F49D5E448EQ36004867-F1D71E4C-78D8-440A-A974-2F65FC3EE621Q36737339-8476FEDD-09E3-442C-A313-C7062BD81783Q36909385-5DE44E35-10A9-4CED-B9C8-0BE925732EE0Q36968175-31A2892D-DA82-4679-AEFA-F608FEA4C877Q37303206-EBE02C1D-5D65-4066-A57D-992AA6A86471Q37680981-94FFC16F-596B-41DD-9517-5470EB936411Q37788217-4A25D1DD-ECCD-43B7-ACF2-49A07C3CF6A8Q37847059-51E0BD11-ACF1-4B44-B751-13ACA5B2B8EDQ37952792-060F8930-5787-4381-BBF4-01F20DFEE069Q38177338-2BCC3352-F74D-42A5-A57C-16F724E6BAF7Q38445355-B0A39C19-AEB2-40F9-B4AD-F9F5D7A74AB9Q39121473-0D04AAF8-5B69-474C-B3A1-A68DC94BF56EQ39622839-EB1F6BAB-72F2-4676-B14B-0CA13D14F079Q40480568-9FECE5D3-0DDE-4791-BF5A-101392D003BDQ42509061-2356D105-8900-43C9-84C2-B16BEA1526D2Q55003785-03363876-8EA6-431A-AC01-8E25E363FE0DQ57821547-840DCA28-E8AF-4119-8BF5-8979C2F275C9
P2860
Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Randomized, controlled trial o ...... s with active Crohn's disease.
@en
Randomized, controlled trial o ...... s with active Crohn's disease.
@nl
type
label
Randomized, controlled trial o ...... s with active Crohn's disease.
@en
Randomized, controlled trial o ...... s with active Crohn's disease.
@nl
prefLabel
Randomized, controlled trial o ...... s with active Crohn's disease.
@en
Randomized, controlled trial o ...... s with active Crohn's disease.
@nl
P2093
P2860
P1476
Randomized, controlled trial o ...... s with active Crohn's disease.
@en
P2093
B D Winston
B Salzberg
RHIL-11 Crohn's Study group
U S Schwertschlag
P2860
P304
P356
10.1046/J.1365-2036.2002.01179.X
P407
P577
2002-03-01T00:00:00Z